Physician profile
Gavin R Powell
NPI 1215933940
$2,745.89
in general payments reported to CMS, 2019-2025
21 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $172 · 2021: $370 · 2022: $248 · 2023: $271 · 2024: $692 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.17 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.94 | 2019-2025 | |
| Janssen Biotech, INC. | $442.15 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $263.34 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $171.94 | 2024 | |
| Genzyme Corporation | $154.78 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $132.09 | 2019-2021 | |
| Leo Pharma INC. | $131.40 | 2022-2025 | Adbry |
| Galderma Laboratories, L.P. | $124.68 | 2019-2025 | Nemluvio, Aklief |
| Organon LLC | $111.55 | 2024-2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $97.92 | 2023-2024 | Zoryve |
| Ucb, INC. | $85.68 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $82.68 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $70.23 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $53.24 | 2019-2022 | |
| Dermavant Sciences, INC. | $38.70 | 2024 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $38.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.11 | 2024 | Dupixent |
| Incyte Corporation | $36.06 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.56 | 2024 | Spevigo |
| Prugen, INC. Pharmaceuticals | $32.76 | 2019-2020 | |
| Merz North America, INC. | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.